Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for global impact. This interview sheds light on the future of cancer treatment and Cartherics’ role in leading the charge towards making cancer a manageable condition. Watch it here: https://www.youtube.com/watch?v=XemSEHsXebk